Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma

References

• Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27(8):1467–1474.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Liang TJ, Gerbes AL, et al. C virus treatment in the real world: optimizing treatment and access to therapies. Gut. 2015;64(11):1824–1833.
   PubMed Web of Science ®Google Scholar
• Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1):S58–68.
   PubMedGoogle Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30(7):1197–1204.
   PubMed Web of Science ®Google Scholar
• Wilder JM, Muir AJ. Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis. 2015;6(6):314–327.
   PubMed Web of Science ®Google Scholar
• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015 Mar 21;385(9973):1124–35. doi: 10.1016/S0140-6736(14)62401-6
   Google Scholar
• Sun P, Yang X, He RQ, et al. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: a systematic review of randomized trials. Hepatol Res. 2014;44(3):259–269.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Chao YC, Lin HH, et al. Systematic review: impact of interferon-based therapy on hcv-related hepatocellular carcinoma. Sci Rep. 2015;5(1):9954.
   PubMedGoogle Scholar
• Roderburg C, Tacke F, Trautwein C. Antiviral therapy in patients with viral hepatitis and hepatocellular carcinoma: indications and prognosis. Visc Med. 2016;32(2):121–126.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology. 2016;64(5):1818–1819.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? Liver Int. 2016;36(6):783–790.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. . PMID: 33479224.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Bonucci C, et al. The (Eternal) debate on microwave ablation versus radiofrequency ablation in bclc-a hepatocellular carcinoma. Vivo. 2020;34(6):3421–3429
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021 Jun;13(8):637–644. Epub 2021 Apr 6. PMID: 33820447.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinomain HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733.
   PubMed Web of Science ®Google Scholar
• Ida H, Hagiwara S, Kono M, et al. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection. Dig Dis. 2017;35(6):565–573.
   PubMed Web of Science ®Google Scholar
• Bielen R, Moreno C, Van Vlierberghe H, et al. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: a Belgian experience. J Viral Hepat. 2017;24(11):976–981.
   PubMed Web of Science ®Google Scholar
• Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65(5):1070–1071.
   PubMed Web of Science ®Google Scholar
• Hassany M, Elsharkawy A, Maged A, et al. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol. 2018 May 31;30(8):876–881. .
   Web of Science ®Google Scholar
• Abdelaziz AO, Nabil MM, Abdelmaksoud AH, et al. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Eur J Gastroenterol Hepatol. 2018;30(1):39–43.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perelló C, et al. PS- 031- Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth. J Hepatol. 2017;66(1):S20.
   Web of Science ®Google Scholar
• Renzulli M, Buonfiglioli F, Conti F, et al. Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol. 2018;28(2):506–513.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2016 Aug 17. [Epub ahead of print]. DOI:10.1002/jmv.24663.
   Web of Science ®Google Scholar
• ANRS collaborative study group on hepatocellular carcinoma (ANRS CO. 22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–740. .
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in hcv patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(996–1005):e1.
   Google Scholar
• Calleja JL, Crespo J, Rincón D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol. 2017;66(6):1138–1148.
   PubMed Web of Science ®Google Scholar
• Zavaglia C, Okolicsanyi S, Cesarini L, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66(1):236‐237. .
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Petta S, Calvaruso V, et al. Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46:688–695.
   PubMed Web of Science ®Google Scholar
• El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017 Apr;24(4):262–267. . Epub 2017 Feb 1. PMID: 28145032.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. conclusions of the barcelona-2000 EASL conference. european association for the study of the liver. J Hepatol. 2001;35(3):421–430.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–67.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple non-invasive index to predict significant fibrosis patients with HIV/HCV co - infection. Hepatology. 2006;43(6):1317–1325. .
   PubMed Web of Science ®Google Scholar
• El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma afterDAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis. J Viral Hepat. 2018;25(6):623–630.
   PubMed Web of Science ®Google Scholar
• Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173–1181.
   PubMed Web of Science ®Google Scholar
• Meer EG, Kohli A, Virtaneva K, et al. Achieving sustained virologic response after interferon-freehepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016;23(7):496–505.
   PubMed Web of Science ®Google Scholar
• Serti E, Park H, Keane M, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. Gut. 2017;66(4):724–735.
   PubMed Web of Science ®Google Scholar
• Lui FH, Moosvi Z, Patel A, et al. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann Gastroenterol. 2020;33(3):293–298.
   PubMed Web of Science ®Google Scholar
• Imai K, Takai K, Hanai T, et al. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. Mol Clin Oncol. 2020;12(2):111–116.
   PubMed Web of Science ®Google Scholar
• Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north american cohort study. Gastroenterology. 2019;156(6):1683–1692.e1.
   PubMed Web of Science ®Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329–337.
   PubMed Web of Science ®Google Scholar
• Messori A, Badiani B, Trippoli S. Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: an Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. Clin Drug Investig. 2015 Dec;35(12):843–850.
   PubMed Web of Science ®Google Scholar
• Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer. 2017 Mar 1;140(5):1042–1049.
   PubMed Web of Science ®Google Scholar
• Iida H, Osaki R, Fujimoto T, et al. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol. 2019;11(1):99–105.
   PubMed Web of Science ®Google Scholar
• Tsai PC, Huang CF, Yu ML. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy. J Hepatol. 2017;66(2):464.
   PubMed Web of Science ®Google Scholar
• Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, Singal AG. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018 Jul;48(2):127–137
   PubMed Web of Science ®Google Scholar
• Chan Y, Macleannan S, Wong J, et al. A78 direct-acting antivirals are not associated with early tumor recurrence after curative treatments in hepatitis c-related hepatocellular carcinoma. J Can Assoc Gastroenterol. 2018;1(Suppl 1):134–135.
   Google Scholar
• Preda CM, Baicus C, Sandra I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy. United European Gastroenterol J. 2019;7(5):699–708.
   PubMed Web of Science ®Google Scholar
• Nakano M, Koga H, Ide T, et al. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. Cancer Med. 2019;8(5):2646–2653.
   PubMed Web of Science ®Google Scholar